BACKGROUND: Catechol-O-methyltransferase (COMT) val(108/158)met (rs4680) is thought to affect dopamine regulated prefrontal cortical activity during working memory (WM) tasks, and to weakly increase risk for developing schizophrenia. Recently, other single nucleotide polymorphisms (SNPs) across the gene have emerged as additional risk factors for schizophrenia: namely rs737865, rs165599, and rs2097603. In a large sample, we examined whether these SNPs affect WM. METHODS: Schizophrenic probands (n = 325), their nonpsychotic siblings (n = 359), and normal control subjects (n = 330) completed tests of WM function. Data were analyzed with a series of mixed model analyses of variance (ANOVAs). RESULTS: Val homozygotes performed most poorly on all conditions of the n-back, irrespective of diagnosis. Additionally, there was a trend towards a disease-only val(108/158)met effect on a test of attentional set-shifting; val homozygote probands performed most poorly. Significant or near-significant effects of rs737865 were found on all conditions of the n-back, with G homozygotes performing worst. There also was a disease-only COMT rs737865 effect on the 0-back. None of the other SNPs showed main effects by themselves. A haplotype constructed from promoter and val(108/158)met SNPs showed main effects on WM parameters, consistent with inverted U models of dopamine signaling. CONCLUSIONS: We extended earlier findings of a val(108/158)met effect on WM function, and suggest that combinations of alleles within COMT may modulate the val(108/158)met effect in a nonlinear manner.
BACKGROUND:Catechol-O-methyltransferase (COMT) val(108/158)met (rs4680) is thought to affect dopamine regulated prefrontal cortical activity during working memory (WM) tasks, and to weakly increase risk for developing schizophrenia. Recently, other single nucleotide polymorphisms (SNPs) across the gene have emerged as additional risk factors for schizophrenia: namely rs737865, rs165599, and rs2097603. In a large sample, we examined whether these SNPs affect WM. METHODS:Schizophrenic probands (n = 325), their nonpsychotic siblings (n = 359), and normal control subjects (n = 330) completed tests of WM function. Data were analyzed with a series of mixed model analyses of variance (ANOVAs). RESULTS:Val homozygotes performed most poorly on all conditions of the n-back, irrespective of diagnosis. Additionally, there was a trend towards a disease-only val(108/158)met effect on a test of attentional set-shifting; val homozygote probands performed most poorly. Significant or near-significant effects of rs737865 were found on all conditions of the n-back, with G homozygotes performing worst. There also was a disease-only COMTrs737865 effect on the 0-back. None of the other SNPs showed main effects by themselves. A haplotype constructed from promoter and val(108/158)met SNPs showed main effects on WM parameters, consistent with inverted U models of dopamine signaling. CONCLUSIONS: We extended earlier findings of a val(108/158)met effect on WM function, and suggest that combinations of alleles within COMT may modulate the val(108/158)met effect in a nonlinear manner.
Authors: Raymond C K Chan; Ronald Y L Chen; Eric Y H Chen; Tomy C K Hui; Eric F C Cheung; H K Cheung; Pak Sham; Tao Li; David Collier Journal: J Int Neuropsychol Soc Date: 2005-03 Impact factor: 2.892
Authors: José A Apud; Venkata Mattay; Jingshan Chen; Bhaskar S Kolachana; Joseph H Callicott; Roberta Rasetti; Guilna Alce; Jennifer E Iudicello; Natkai Akbar; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: Neuropsychopharmacology Date: 2006-10-25 Impact factor: 7.853
Authors: A Meyer-Lindenberg; T Nichols; J H Callicott; J Ding; B Kolachana; J Buckholtz; V S Mattay; M Egan; D R Weinberger Journal: Mol Psychiatry Date: 2006-06-20 Impact factor: 15.992
Authors: Giuseppe Blasi; Venkata S Mattay; Alessandro Bertolino; Brita Elvevåg; Joseph H Callicott; Saumitra Das; Bhaskar S Kolachana; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: J Neurosci Date: 2005-05-18 Impact factor: 6.167
Authors: Andreas Meyer-Lindenberg; Philip D Kohn; Bhaskar Kolachana; Shane Kippenhan; Aideen McInerney-Leo; Robert Nussbaum; Daniel R Weinberger; Karen Faith Berman Journal: Nat Neurosci Date: 2005-04-10 Impact factor: 24.884
Authors: Sandra Jazbec; Christos Pantelis; Trevor Robbins; Thomas Weickert; Daniel R Weinberger; Terry E Goldberg Journal: Schizophr Res Date: 2006-10-19 Impact factor: 4.939
Authors: Krista M Wisner; Brita Elvevåg; James M Gold; Daniel R Weinberger; Dwight Dickinson Journal: Schizophr Res Date: 2010-10-28 Impact factor: 4.939
Authors: Alan E Ceaser; Terry E Goldberg; Michael F Egan; Robert P McMahon; Daniel R Weinberger; James M Gold Journal: Biol Psychiatry Date: 2008-07-02 Impact factor: 13.382
Authors: Jaime L Tartar; Dominick Cabrera; Sarah Knafo; Julius D Thomas; Jose Antonio; Corey A Peacock Journal: J Sports Sci Med Date: 2020-02-24 Impact factor: 2.988
Authors: Moriah E Thomason; Robert F Dougherty; Natalie L Colich; Lee M Perry; Elena I Rykhlevskaia; Hugo M Louro; Joachim F Hallmayer; Christian E Waugh; Roland Bammer; Gary H Glover; Ian H Gotlib Journal: Neuroimage Date: 2010-01-18 Impact factor: 6.556